Under the terms of the agreement, Schering-Plough shareholders will receive just over half a Merck share and $10.50 in cash for each Schering-Plough share they own. Each Merck share will automatically become a share of the combined company.
Merck shareholders are expected to own approximately 68 percent of the combined company, and Schering-Plough shareholders are expected to own approximately 32 percent.
Merck Chairman, President and Chief Executive Officer Richard T. Clark will lead the combined company.
"We are creating a strong, global healthcare leader built for sustainable growth and success," Clark said in a media statement Monday. "The combined company will benefit from a formidable research and development pipeline, a significantly broader portfolio of medicines and an expanded presence in key international markets, particularly in high-growth emerging markets.
0 Kommentare:
Post a Comment